Pembrolizumab and Oral Metronomic Cyclophosphamide in Patients with Chest Wall Breast Cancer (PERICLES): an immune-biomarker analysis of tumor infiltrating lymphocytes (TILs) and programmed cell death ligand protein 1 (PD-L1)

被引：1
|
作者：
Valenza, Carmine
Giachetti, Pier Paolo Maria Berton
Zagami, Paola
Nicolo, Eleonora
Trapani, Dario
Boldrini, Laura
Salimbeni, Beatrice Taurelli
Ascione, Liliana
Antonarelli, Gabriele
Corti, Chiara
Esposito, Angela
Criscitiello, Carmen
Fusco, Nicola
Curigliano, Giuseppe
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 05期
关键词：
D O I：
10.1158/1538-7445.SABCS22-P1-14-05
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1-14-05
引用
收藏
页数：4
相关论文
共 50 条
  • [1] Significance of evaluating tumor-infiltrating lymphocytes (TILs) and programmed cell death-ligand 1 (PD-L1) expression in breast cancer
    Kurozumi, Sasagu
    Fujii, Takaaki
    Matsumoto, Hiroshi
    Inoue, Kenichi
    Kurosumi, Masafumi
    Horiguchi, Jun
    Kuwano, Hiroyuki
    MEDICAL MOLECULAR MORPHOLOGY, 2017, 50 (04) : 185 - 194
  • [2] Significance of evaluating tumor-infiltrating lymphocytes (TILs) and programmed cell death-ligand 1 (PD-L1) expression in breast cancer
    Sasagu Kurozumi
    Takaaki Fujii
    Hiroshi Matsumoto
    Kenichi Inoue
    Masafumi Kurosumi
    Jun Horiguchi
    Hiroyuki Kuwano
    Medical Molecular Morphology, 2017, 50 : 185 - 194
  • [3] Expression of programmed cell death ligand 1 (PD-L1) and prevalence of tumor-infiltrating lymphocytes (TILs) in chordoma
    Feng, Yong
    Shen, Jacson
    Gao, Yan
    Liao, Yunfei
    Cote, Gregory
    Choy, Edwin
    Chebib, Ivan
    Mankin, Henry
    Hornicek, Francis
    Duan, Zhenfeng
    ONCOTARGET, 2015, 6 (13) : 11139 - 11149
  • [4] Expression of programmed death ligand-1 (PD-L1) and tumor infiltrating lymphocytes (TILs) in breast carcinoma and their clinical significance
    Mondal, Santosh Kumar
    Bhattacharya, Saptarshi
    Sarkar, Aditya Prasad
    Saha, Rama
    JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2023, 19 (SUPPL 1) : S81 - S86
  • [5] Prognostic Significance of Tumor Infiltrating Lymphocytes (TILs) and Programmed Cell Death-Ligand 1 (PD-L1) in Nasopharyngeal Carcinoma
    Zhou, F.
    Wang, J.
    Shayan, G.
    Huang, X.
    Wang, K.
    Qu, Y.
    Chen, X.
    Wu, R.
    Zhang, Y.
    Sun, S.
    Luo, J.
    Liu, Q.
    Zhang, J.
    Xiao, J.
    Yi, J.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2021, 111 (03): : E388 - E389
  • [6] Predictive value of tumor-infiltrating lymphocytes (TILs) and programmed cell death-ligand 1 (PD-L1) expression in breast cancer patients treated with neoadjuvant chemotherapy
    Rashed, Hayam E.
    Muhammad, Shireen S.
    Sameh, Reham
    Elsebai, Eman
    Nawar, Nashwa
    Abdelhamid, Mohamed I.
    Abdelaziz, Lobna A.
    REVISTA DE SENOLOGIA Y PATOLOGIA MAMARIA, 2021, 34 (04): : 200 - 207
  • [7] Programmed cell death ligand 1(PD-L1), Programmed death 1+(PD-1) lymphocytes and Tumor infiltrating lymphocytes (TILs): are they playing a role in predicting response to anti-PD-1 therapies?
    Bennati, Chiara
    Leonardi, Giulia
    Sidoni, Angelo
    Gili, Alessio
    Ricciuti, Biagio
    Minotti, Vincenzo
    Chiari, Rita
    Metro, Giulio
    Ludovini, Vienna
    Colabrese, Daniela
    Matocci, Roberta
    Crino, Lucio
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [8] Programmed death ligand 1 (PD-L1) in colon cancer and its interaction with budding and tumor-infiltrating lymphocytes (TILs) as tumor-host antagonists
    Lang-Schwarz, Corinna
    Melcher, Balint
    Hartmann, Arndt
    Bertz, Simone
    Dregelies, Theresa
    Lang-Schwarz, Klaus
    Vieth, Michael
    Sterlacci, William
    INTERNATIONAL JOURNAL OF COLORECTAL DISEASE, 2021, 36 (11) : 2497 - 2510
  • [9] Programmed death ligand 1 (PD-L1) in colon cancer and its interaction with budding and tumor-infiltrating lymphocytes (TILs) as tumor-host antagonists
    Corinna Lang-Schwarz
    Balint Melcher
    Arndt Hartmann
    Simone Bertz
    Theresa Dregelies
    Klaus Lang-Schwarz
    Michael Vieth
    William Sterlacci
    International Journal of Colorectal Disease, 2021, 36 : 2497 - 2510
  • [10] The therapeutic candidate for immune checkpoint inhibitors elucidated by the status of tumor-infiltrating lymphocytes (TILs) and programmed death ligand 1 (PD-L1) expression in triple negative breast cancer (TNBC)
    Nobumoto Tomioka
    Manabu Azuma
    Mayuko Ikarashi
    Mitsugu Yamamoto
    Masako Sato
    Ken-ichi Watanabe
    Katsushige Yamashiro
    Masato Takahashi
    Breast Cancer, 2018, 25 : 34 - 42
12345